OR WAIT null SECS
February 25, 2022
FDA approves Jardiance (empagliflozin) for wider range of patients with heart failure.
February 24, 2022
FDA licenses Certara’s Immunogenicity Simulator to research and evaluate immunogenicity in protein-based therapeutics.
AstraZeneca and Honeywell will partner to develop next-generation respiratory inhalers as part of AstraZeneca’s Ambition Zero Carbon program.
A new portfolio of chromatography and mass spectrometry consumables launched by Thermo Fisher Scientific is designed to meet higher performance requirements while remaining economical.
TFF Pharmaceuticals announces findings that inhaled niclosamide significantly inhibits viral replication of the Omicron variant of SARS-CoV-2.
Medicago and GSK have announced that Health Canada has approved COVIFENZ, an adjuvanted plant-based COVID-19 vaccine.
USP is developing mRNA quality guidelines to help companies and regulators bring innovative medicines to market faster.
Janssen will pay upwards of $1 billion for exclusive rights to use Remix’s RNA-based drug discovery platform on three specific targets.
Eli Lilly and Company are investing $700 million into a Boston-based facility for the newly announced Institute for Genetic Medicine.
Taconic Biosciences Cage+ colony management service aims to offer comprehensive coverage for contract breeding services.